FDA warns ALVA-AMCO that Nauzene Kids, a children’s nausea drug, is an unapproved new drug.
What happened
FDA reviewed www.nauzenekids.com in May 2023 and found that ALVA-AMCO offers Nauzene Kids for sale in the United States. The label and website claim the product relieves nausea and upset stomachs, including from car sickness and stomach flu. FDA determined it is an unapproved new drug and referenced a July 26, 2023 warning letter to Denison Pharmaceuticals about significant current good manufacturing practice (CGMP), the quality rules for drug manufacturing, violations.
What FDA found
FDA says Nauzene Kids is a new drug because its label and website claims say it treats nausea, upset stomach, car sickness, and stomach flu, and it is not generally recognized as safe and effective for those uses.
FD&C Act sections 201(p) and 505(a), 21 U.S.C. 321(p) and 355(a)FDA says the firm introduces or delivers the product into interstate commerce without an FDA-approved drug application.
FD&C Act sections 301(d) and 505(a), 21 U.S.C. 331(d) and 355(a)FDA says the product label and website claims show the product is intended to treat disease or affect the structure or function of the body.
FD&C Act section 201(g)(1), 21 U.S.C. 321(g)(1)FDA says calling the product homeopathic does not exempt it from drug approval, misbranding, or adulteration requirements.
FD&C Act section 201(g)(1), 21 U.S.C. 321(g)(1)
What FDA wants
FDA asks the company to notify it in writing within 15 working days of the specific steps taken to correct the violations and prevent recurrence, with supporting documents. If correction cannot be completed in that time, the company must state why and when it will finish.
Who should pay attention
- retailers and websites that sell Nauzene Kids
- parents and caregivers of young children
- drug companies using Denison Pharmaceuticals as a contract manufacturer
This is a summary. Read the original letter on fda.gov.